Physician profile
Frank Bain
NPI 1174537898
$800.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $119 · 2022: $56.19 · 2023: $216 · 2024: $29.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115.68 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $104.13 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $77.41 | 2019-2024 | Breztri |
| Amgen INC. | $68.71 | 2019-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $62.85 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $56.05 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $52.86 | 2019-2020 | |
| Amarin Pharma, INC. | $43.15 | 2019 | |
| Avanir Pharmaceuticals, INC. | $42.38 | 2019 | |
| Genentech USA, INC. | $38.25 | 2019-2020 | |
| Astellas Pharma US INC | $26.48 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $25.59 | 2019-2020 | |
| Abbvie INC. | $17.82 | 2023 | Ubrelvy |
| Amag Pharmaceuticals, INC. | $14.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2019 | |
| Lilly USA, LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.